hydrophilic status may increase progression-free survival in IBC
 

I mean't hydrophilic statins, but don't know how to correct the subject line!!!


Br J Cancer. 2013 Jul 2. doi: 10.1038/bjc.2013.342. [Epub ahead of print]
Statin use in primary inflammatory breast cancer: a cohort study.
Brewer TM, Masuda H, Liu DD, Shen Y, Liu P, Iwamoto T, Kai K, Barnett CM, Woodward WA, Reuben JM, Yang P, Hortobagyi GN, Ueno NT.
Source
1] Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA [2] School of Medicine, Eastern Virginia Medical School, Norfolk, VA 23501, USA.
Abstract
Background:Some studies have suggested that statins, which have cholesterol-lowering and anti-inflammatory properties, may have antitumor effects. Effects of statins on inflammatory breast cancer (IBC) have never been studied.Methods:We reviewed 723 patients diagnosed with primary IBC in 1995-2011 and treated at The University of Texas MD Anderson Cancer Center. Statin users were defined as being on statins at the initial evaluation. Based on Ahern et al's statin classification (JNCI, 2011), clinical outcomes were compared by statin use and type (weakly lipophilic to hydrophilic (H-statin) vs lipophilic statins (L-statin)). We used the Kaplan-Meier method to estimate the median progression-free survival (PFS), overall survival (OS) and disease-specific survival (DSS), and a Cox proportional hazards regression model to test the statistical significance of potential prognostic factors.Results:In the multivariable Cox model, H-statins were associated with significantly improved PFS compared with no statin (hazard ratio=0.49; 95% confidence interval=0.28-0.84; P<0.01); OS and DSS P-values were 0.80 and 0.85, respectively. For L-statins vs no statin, P-values for PFS, DSS, and OS were 0.81, 0.4, and 0.74, respectively.Conclusion:H-statins were associated with significantly improved PFS. A prospective randomised study evaluating the survival benefits of statins in primary IBC is warranted.British Journal of Cancer advance online publication, 2 July 2013 doi:10.1038/bjc.2013.342 www.bjcancer.com.
PMID: 23820253

Re: hydrophilic status may increase progression-free survival in IBC
 

Have recently read that statins improve survival for inflammatory bc, but dangerous for other bc's. any thoughts, anyone? am on statins, but temporarily suspended use till i'm more comfortable about the below pasted study.
<LI class="middle even sf-item-2 sf-depth-1 sf-total-children-9 sf-parent-children-0 sf-single-children-9 menuparent" id=menu-110663-1 jQuery1377609202021="73"><LI class="middle odd sf-item-3 sf-depth-1 sf-total-children-3 sf-parent-children-0 sf-single-children-3 menuparent" id=menu-110728-1 hoverIntent_t="undefined" jQuery1377609202021="74">http://ad1.greenmedinfo.com/www/deli...&cb=2c0139106a
<NOSCRIPT></NOSCRIPT>



<!--Long-term statin use is associated with an increased risk of ductal and lobular breast cancer among women 55-74 years of age.

-->Long-term statin use is associated with an increased risk of ductal and lobular breast cancer among women 55-74 years of age. - GreenMedInfo Summary


Abstract Title:
Long-term statin use and risk of ductal and lobular breast cancer among women 55-74 years of age.



Abstract Source:

Cancer Epidemiol Biomarkers Prev. 2013 Jul 5. Epub 2013 Jul 5. PMID: 23833125




Abstract Author(s):
Jean A McDougall, Kathleen E Malone, Janet R Daling, Kara L Cushing-Haugen, Peggy L Porter, Christopher I Li



Article Affiliation:
Epidemiology, Fred Hutchinson Cancer Research Center.



Abstract:
Background: Mechanistic studies largely support the chemopreventive potential of statins. However, results of epidemiologic studies investigating statin use and breast cancer risk have been inconsistent and lacked the ability to evaluate long-term statin use. Methods: We utilized data from a population-based case-control study of breast cancer conducted in the Seattle-Puget Sound region to investigate the relationship between long-term statin use and breast cancer risk. 916 invasive ductal carcinoma (IDC) and 1,068 invasive lobular carcinoma (ILC) cases 55-74 years of age diagnosed between 2000 and 2008 were compared to 902 control women. All participants were interviewed in-person and data on hypercholesterolemia and all episodes of lipid lowering medication use were collected through a structured questionnaire. We assessed the relationship between statin use and IDC and ILC risk using polytomous logistic regression. Results: Current users of statins for 10 years or longer had a 1.83-fold increased risk of IDC [95% confidence interval (CI): 1.14-2.93] and a 1.97-fold increased risk of ILC (95% CI: 1.25-3.12) compared to never users of statins. Among women diagnosed with hypercholesterolemia, current users of statins for 10 years or longer had more than double the risk of both IDC [odds ratio (OR): 2.04, 95% CI: 1.17-3.57] and ILC (OR: 2.43, 95% CI: 1.40-4.21) compared to never users. Conclusion: In this contemporary population-based case-control study long-term use of statins was associated with increased risks of both IDC and ILC. Impact: Additional studies with similarly high frequencies of statin use for various durations are needed to confirm this novel finding.




Article Published Date : Jul 04, 2013